KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Working Capital Changes (2018 - 2025)

Castle Biosciences' Other Working Capital Changes history spans 7 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 166.28% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$1.3 million, down 211.65%, while the annual FY2025 figure was -$1.3 million, 211.65% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$1.3 million at Castle Biosciences, up from -$4.6 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $5.2 million in Q2 2025 and bottomed at -$4.6 million in Q3 2025.
  • The 5-year median for Other Working Capital Changes is -$34500.0 (2022), against an average of $66300.0.
  • The largest annual shift saw Other Working Capital Changes plummeted 2280.52% in 2021 before it surged 8059.38% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.4 million in 2021, then soared by 230.05% to $1.8 million in 2022, then plummeted by 102.28% to -$40000.0 in 2023, then skyrocketed by 5112.5% to $2.0 million in 2024, then plummeted by 166.28% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Other Working Capital Changes are -$1.3 million (Q4 2025), -$4.6 million (Q3 2025), and $5.2 million (Q2 2025).